Avid Bioservices Inc (CDMO)

[semper]

BIOWORLD TODAY TM
THE DAILY BIOPHARMACEUTICAL NEWS SOURCE
BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS
JUNE 1, 2015

OTHER NEWS TO NOTE Page 8 of 11
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said the
company entered a sponsored research agreement with
Memorial Sloan Kettering Cancer Center (MSK) to explore the
potential of Peregrine’s phosphatidylserine (PS)-targeting
antibody platform, with the goal of identifying effective
treatment combinations based on PS-targeting agents,
including Peregrine’s lead clinical agent, bavituximab, with
other checkpoint inhibitors or immune-stimulating agents
that will further guide the bavituximab clinical development
program. Specifically, MSK researchers will examine the
combination of bavituximab alongside models of checkpoint
blockade that are unresponsive to inhibition or co-stimulation
given the ability of bavituximab to reprogram myeloid-derived
suppressor cells and increase tumoricidal T cells in tumors,
a mechanism of action that is complementary to checkpoint
blockade and T-cell activation.
http://www.sofinnova.fr/wp-content/uploads/2015/06/BWT06012015-2.pdf